c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs

Journal of Clinical Investigation

Volumn 116, Issue 2, 2006, Pages 528-535

  Takasu, Hisashi ^a,b   Sugita, Atsuko ^b   Uchiyama, Yasushi ^b   Katagiri, Nobuyoshi ^a   Okazaki, Makoto ^b   Ogata, Etsuro ^b,c   Ikeda, Kyoji ^a  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 [[1 [1 [(2 ETHYL 2 HYDROXYBUTYL)THIO]ETHYL] 3,3A,5,6,7,7A HEXAHYDRO 7A METHYL 4H INDEN 4 YLIDENE]ETHYLIDENE] 4 METHYLENE 1,3 CYCLOHEXANEDIOL; CALCITRIOL; COLONY STIMULATING FACTOR 1; DD 281; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN; PROTEIN C FOS; RECEPTOR ACTIVATOR OF NF KAPPA B; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CALCIUM ABSORPTION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL ISOLATION; CELL NUCLEUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG TARGETING; FEMALE; GENE EXPRESSION SYSTEM; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCITRIOL; CARRIER PROTEINS; CELL DIFFERENTIATION; FEMALE; GLYCOPROTEINS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOPOROSIS; OSTEOPROTEGERIN; OVARIECTOMY; PROTO-ONCOGENE PROTEINS C-FOS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CALCITRIOL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 32444433446     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI24742     Document Type: Article

References (40)

1. Cummings, S.R., and Melton, L.J. 2002. Epidemiology and outcomes of osteoporotic fractures. Lancet. 359:1761-1767.
2. Teitelbaum, S.L. 2000. Bone resorption by osteoclasts. Science. 289:1504-1508.
3. Suda, T., et al. 1999. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20:345-357.
4. Karsenty, G., and Wagner, E.F. 2002. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell. 2:389-406.
5. Parfitt, A.M., et al. 1996. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J. Bone Miner. Res. 11:150-159.
6. Rodan, G.A., and Martin, T.J. 2000. Therapeutic approaches to bone diseases. Science. 289:1508-1514.
7. Shiraishi, A., et al. 2000. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J. Bone Miner. Res. 15:770-779.
8. Uchiyama, Y., et al. 2002. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone. 30:582-588.
9. Shibata, T., et al. 2002. Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. J. Bone Miner. Res. 17:622-629.
10. Manolagas, S.C., and Jilka, R.L. 1995. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med. 332:305-311.
11. Pacifici, R. 1996. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J. Bone Miner. Res. 11:1043-1051.
12. Shevde, N.K., Bendixen, A.C., Dienger, K.M., and Pike, J.W. 2000. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc. Natl. Acad. Sci. U. S. A. 97:7829-7834.
13. Simonet, W.S., et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89:309-319.
14. Bucay, N., et al. 1998. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:1260-1268.
15. Reichel, H., Koeffler, H.P., and Norman, A.W. 1989. The role of the vitamin D endocrine system in health and disease. N. Engl. J. Med. 320:980-991.
16. Ferrara, P., et al. 2003. The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression. Oncogene. 22:1461-1474.
17. Grigoriadis, A.E., et al. 1994. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science. 266:443-448.
18. Matsuo, K., et al. 2000. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat. Genet. 24:184-187.
19. Takayanagi, H., et al. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell. 3:889-901.
20. Takayanagi, H., et al. 2002. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 416:744-749.
21. Matsuo, K., et al. 2004. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J. Biol. Chem. 279:26475-26480.
22. Yoshizawa, T., et al. 1997. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. 16:391-396.
23. Thomas, M.K., et al. 1998. Hypovitaminosis D in medical inpatients. N. Engl. J. Med. 338:777-783.
24. Trivedi, D.P., Doll, R., and Khaw, K.T. 2003. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ. 326:469-475.
25. Hauselmann, H.J., and Rizzoli, R. 2003. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos. Int. 14:2-12.
26. Papadimitropoulos, E., et al. 2002. Meta-analyses of therapies for postmenopausal osteoporosis. VIII. Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr. Rev. 23:560-569.
27. Raisz, L.G., Trummel, C.L., Holick, M.F., and DeLuca, H.F. 1972. 1,25-Dihydroxycholecalciferol: a potent stimulator of bone resorption in tissue culture. Science. 175:768-769.
28. Yasuda, H., et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 95:3597-3602.
29. Itonaga, I., Sabokbar, A., Neale, S.D., and Athanasou, N.A. 1999. 1,25-Dihydroxyvitamin D(3) and prostaglandin E(2) act directly on circulating human osteoclast precursors. Biochem. Biophys. Res. Commun. 264:590-595.
30. Shiraishi, A., et al. 1999. The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif. Tissue Int. 65:311-316.
31. Ueno, Y., et al. 2003. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J. Cell. Biochem. 90:267-277.
32. Matsumoto, T., et al. 2005. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab. 90:5031-5036.
33. Lips, P. 2001. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr. Rev. 22:477-501.
34. Endo, K., et al. 2000. 1,25-Dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion. J. Bone Miner. Res. 15:175-181.
35. Choi, S.J., et al. 1999. Identification of human asparaginyl endopeptidase (legumain) as an inhibitor of osteoclast formation and bone resorption. J. Biol. Chem. 274:27747-27753.
36. Zhou, H., et al. 2001. A novel osteoblast-derived C-type lectin that inhibits osteoclast formation. J. Biol. Chem. 276:14916-14923.
37. Schrader, M., Kahlen, J.P., and Carlberg, C. 1997. Functional characterization of a novel type of 1 alpha,25-dihydroxyvitamin D3 response element identified in the mouse c-fos promoter. Biochem. Biophys. Res. Commun. 230:646-651.
38. Candeliere, G.A., Prud'homme, J., and St-Arnaud, R. 1991. Differential stimulation of fos and jun family members by calcitriol in osteoblastic cells. Mol. Endocrinol. 5:1780-1788.
39. Shevde, N.K., et al. 2002. A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation. Proc. Natl. Acad. Sci. U. S. A. 99:13487-13491.
40. Peleg, S., Uskokovic, M., Ahene, A., Vickery, B., and Avnur, Z. 2002. Cellular and molecular events associated with the bone-protecting activity of the noncalcemic vitamin D analog Ro-26-9228 in osteopenic rats. Endocrinology. 143:1625-1636.